CD8A and neoplasm: ,116,117 Notably, doxorubicin can induce immunogenic cell death in tumor cells, promoting the release of damage-associated molecular patterns, which, in turn, can facilitate the priming of tumor-specific CD8+ T cells and activate STING pathway.118